Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

The influence of cannabinoids on generic traits of neurodegeneration.

Fagan SG, Campbell VA.

Br J Pharmacol. 2014 Mar;171(6):1347-60. doi: 10.1111/bph.12492. Review.

2.

Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.

Fernández-Ruiz J, Moro MA, Martínez-Orgado J.

Neurotherapeutics. 2015 Oct;12(4):793-806. doi: 10.1007/s13311-015-0381-7. Review.

3.

The multiplicity of action of cannabinoids: implications for treating neurodegeneration.

Gowran A, Noonan J, Campbell VA.

CNS Neurosci Ther. 2011 Dec;17(6):637-44. doi: 10.1111/j.1755-5949.2010.00195.x. Epub 2010 Sep 28. Review.

PMID:
20875047
4.

Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target.

Cassano T, Calcagnini S, Pace L, De Marco F, Romano A, Gaetani S.

Front Neurosci. 2017 Feb 2;11:30. doi: 10.3389/fnins.2017.00030. eCollection 2017. Review.

5.

Alzheimer's disease; taking the edge off with cannabinoids?

Campbell VA, Gowran A.

Br J Pharmacol. 2007 Nov;152(5):655-62. Epub 2007 Sep 10. Review.

6.

Cannabinoids and neurodegenerative diseases.

Romero J, Orgado JM.

CNS Neurol Disord Drug Targets. 2009 Dec;8(6):440-50. Review.

PMID:
19839933
7.

Therapeutic potential of cannabinoids in neurodegenerative disorders: a selective review.

Velayudhan L, Van Diepen E, Marudkar M, Hands O, Suribhatla S, Prettyman R, Murray J, Baillon S, Bhattacharyya S.

Curr Pharm Des. 2014;20(13):2218-30. Review.

PMID:
23829360
8.

The endocannabinoid system as a target for the treatment of motor dysfunction.

Fernández-Ruiz J.

Br J Pharmacol. 2009 Apr;156(7):1029-40. doi: 10.1111/j.1476-5381.2008.00088.x. Epub 2009 Feb 13. Review.

9.

Cannabinoids: clearing the smoke on pain, inflammation and neurodegeneration.

Downer EJ, Finn DP.

Br J Pharmacol. 2014 Mar;171(6):1341-4. doi: 10.1111/bph.12642.

10.

Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease.

Little JP, Villanueva EB, Klegeris A.

Mini Rev Med Chem. 2011 Jun;11(7):582-90. Review.

PMID:
21699489
11.

The endocannabinoid system in normal and pathological brain ageing.

Bilkei-Gorzo A.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3326-41. doi: 10.1098/rstb.2011.0388. Review.

12.

Cannabinoids and neuroprotection in motor-related disorders.

de Lago E, Fernández-Ruiz J.

CNS Neurol Disord Drug Targets. 2007 Dec;6(6):377-87. Review.

PMID:
18220777
13.

Endocannabinoid System in Neurological Disorders.

Ranieri R, Laezza C, Bifulco M, Marasco D, Malfitano AM.

Recent Pat CNS Drug Discov. 2016;10(2):90-112. Review.

PMID:
27364363
14.

Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.

Basavarajappa BS, Nixon RA, Arancio O.

Mini Rev Med Chem. 2009 Apr;9(4):448-62. Review.

15.

Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.

Fernández-Ruiz J, Romero J, Ramos JA.

Handb Exp Pharmacol. 2015;231:233-59. doi: 10.1007/978-3-319-20825-1_8. Review.

PMID:
26408163
16.

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

ACS Chem Neurosci. 2012 May 16;3(5):400-6. doi: 10.1021/cn200114w. Epub 2012 Feb 9.

17.

Prospects for cannabinoid therapies in basal ganglia disorders.

Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA.

Br J Pharmacol. 2011 Aug;163(7):1365-78. doi: 10.1111/j.1476-5381.2011.01365.x. Review.

18.

Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.

Rodríguez-Cueto C, Benito C, Fernández-Ruiz J, Romero J, Hernández-Gálvez M, Gómez-Ruiz M.

Br J Pharmacol. 2014 Mar;171(6):1472-89. doi: 10.1111/bph.12283.

19.

Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability.

Alhamoruni A, Wright KL, Larvin M, O'Sullivan SE.

Br J Pharmacol. 2012 Apr;165(8):2598-610. doi: 10.1111/j.1476-5381.2011.01589.x.

20.

Cannabinoids and neuroinflammation.

Walter L, Stella N.

Br J Pharmacol. 2004 Mar;141(5):775-85. Epub 2004 Feb 2. Review.

Supplemental Content

Support Center